Seattle Genetics, Takeda Highlight Publication 'Blood' Final Long-Term Survival Data From ADCETRIS Phase 2 Trial: 'Estimated 5-Year Overall Survival Rate 60%, 5-Year Progression-Free Survival Rate 39%'